EHA 2021 | Future role of CAR-T in AML

Name: Future role of CAR-T in AML
Uploaded: 2021-06-21T00:00:00Z
Duration: 59 s
Description: Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the future role of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of acute myeloid leukemia (AML). In particular, Dr Haubner highlights the need to improve manufacturing and manage toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sascha Haubner • 21 Jun 2021

EHA 2021

Acute Myeloid Leukemia Leukemia CAR-T

Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the future role of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of acute myeloid leukemia (AML). In particular, Dr Haubner highlights the need to improve manufacturing and manage toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.